Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gpASIT+ in Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT03724240Phase 3Unknown
- Sponsor
- ASIT Biotech
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing gpASIT+ with Placebo (2 arms). Primary endpoint: Average daily Combined Symptom and Medication Score during the peak of the grass pollen season. Status: unknown.
02
Drugs
gpASIT+
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT03724240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724240.